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https://doi.org/10.1016/j.stemcr.2019.04.006SUMMARYInduction of pluripotency in somatic cells with defined genetic factors has been successfully used to investigate themechanisms of disease
initiation and progression. Cellular reprogramming and oncogenic transformation share common features; both involve undergoing a dra-
matic change in cell identity, and immortalization is a key step for cancer progression that enhances reprogramming. However, there are
very few examples of complete successful reprogramming of tumor cells. Here we address the effect of expressing an active oncogene, RAS,
on the process of reprogramming and found that, while combined expression with reprogramming factors enhanced dedifferentiation,
expression within the context of neoplastic transformation impaired reprogramming. RAS induces expression changes that promote
loss of cell identity and acquisition of stemness in a paracrine manner and these changes result in reprogramming when combined with
reprogramming factors. When cells carry cooperating oncogenic defects, RAS drives cells into an incompatible cellular fate of malignancy.INTRODUCTION
The development of an in vitro cellular system allowing the
reprogramming of differentiated somatic cells into induced
pluripotent stem cells (iPSCs) by expression of defined ge-
netic elements, represents an opportunity to advance in
many different areas of biomedical research (Takahashi
and Yamanaka, 2016). Apart from providing pluripotent
cells to develop cell therapies, reverting the differentiated
state of the cell offers an opportunity to create faithful dis-
ease models and to develop powerful cellular platforms in
which to efficiently screen pharmacological interventions
(Onder and Daley, 2012).
The application of cellular reprogramming to the study
of cancer is just beginning to be explored (Papapetrou,
2016). One particularly interesting aspect of the applica-
tion of cellular reprogramming to the study of cancer is
the similarity between reprogramming and neoplastic
transformation (Goding et al., 2014). During reprogram-
ming, cells need to overcome barriers that oppose the
drastic change in cell identity characterizing this process
and gain the capacity to proliferate indefinitely. Tumor
cells, on the other hand, are generally immortal and typi-
cally display the features of an undifferentiated state, espe-
cially inmore advanced cancers. For example, poorly differ-
entiated tumors present an embryonic stem-like geneStem Cell R
This is an open access article under the Csignature that is considered a hallmark of aggressiveness
(Ben-Porath et al., 2008), and cancer cell dedifferentiation
has been proposed as a means to become more malignant
(Bradner et al., 2017). Elucidating the common mecha-
nisms and barriers shared by reprogramming and transfor-
mation could illuminate the molecular bases underlying
the pathogenesis of cancer.
Illustrating that common barriers prevent cell transfor-
mation and cell reprogramming is the observation that
cells deficient in tumor suppressor genes which regulate
immortality, renders cells susceptible to the transforming
activity of activated oncogenes and enhances reprogram-
ming (Hong et al., 2009; Kawamura et al., 2009; Li et al.,
2009; Marión et al., 2009; Utikal et al., 2009). Actually,
the expression of a single oncogene on a normal differenti-
ated cell does not lead to neoplastic transformation.
Immortality is required to overcome the barriers that block
the transformation into a cancer cell (Land et al., 1983;
Ruley, 1983). Since immortalization is a pre-requisite for
transformation, one would expect cancer cells to be more
susceptible to reprogramming. However, there are strik-
ingly few examples of successful complete reprogramming
to pluripotency in cancer cells (Ramos-Mejia et al., 2012).
Using the system of cellular reprogramming has
already proved extremely useful to identify previously un-
recognized activities of tumor suppressors, such as theeports j Vol. 12 j 1099–1112 j May 14, 2019 j ª 2019 The Authors. 1099
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transcriptional control over pluripotency gene Sox2 ex-
erted by cell-cycle inhibitors p27Kip1 and the retinoblas-
toma family of pocket proteins (Kareta et al., 2015; Li
et al., 2012; Vilas et al., 2015). Similarly, it could also
represent an opportunity to gain insight into the
molecular mechanisms of cellular transformation driven
by oncogenes.
In this work, we decided to address the effect of express-
ing oncogenic RAS on the process of cellular reprogram-
ming. RAS was the first human oncogene isolated from a
tumor and it is one of the most frequently mutated genes
in human cancer (Malumbres and Barbacid, 2003). First,
we evaluated the consequences of introducing RAS as
part of the reprogramming cocktail together with Oct4,
Sox2, Klf4, and c-Myc (OSKM). Introduction of activated
RAS alone on normal differentiated somatic cells does not
lead to neoplastic transformation and requires the presence
of cooperating oncogenes to allow progression into malig-
nancy (Serrano et al., 1997). Interestingly, in our case the
combined expression of RAS and the reprogramming fac-
tors resulted in enhanced reprogramming. This effect of
RAS is non-cell autonomous and seems to be a reflection
of an endogenous activity played by the oncogene during
early stages of a normal reprogramming process. In
contrast, expression of oncogenic RAS in the context of
full transformation blocks reprogramming. Using in vivo
systems, we conclude that oncogene activation generates
a tissuemicroenvironment that renders cells in the vicinity
susceptible to dedifferentiation, while transformation and
reprogramming seem to be alternative non-compatible
cell fates.RESULTS
RAS Expression Enhances Cellular Reprogramming
To address the effect of oncogene expression on the process
of cellular reprogramming, we overexpressed an oncogenic
mutantHras,HrasV12, inmouse embryo fibroblasts (MEFs)
derived from i4F mice, a transgenic animal carrying a poly-
cistronic tetracycline-inducible cassette expressing the re-
programming factors: Oct4, Sox2, Klf4, and c-Myc (Abad
et al., 2013). After 14 days in doxycycline, iPSC colonies
were stained using alkaline phosphatase (AP). The number
of colonies was increased when we overexpressed onco-
genic Hras compared with the overexpression of GFP as a
control (Figure 1A). Similar results were obtained when
we co-expressed the reprogramming factors together with
HrasV12 using retroviral transduction (Figure S1A). To
verify pluripotency, colonies were picked and expanded
for further analysis. Embryonic stem cell markers, their ca-
pacity to differentiate in vitro, and the ability to form
embryoid bodies or teratomas with the expression of1100 Stem Cell Reports j Vol. 12 j 1099–1112 j May 14, 2019markers of the three germ layers in vivo confirmed their plu-
ripotency (Figures S1B–S1E). Thus, expression of oncogenic
Hras can enhance reprogramming by OSKM.
Other members of the RAS family or downstream of RAS
were also effective.NrasV12, and an active version of one of
the RAF family members, BrafV600E, a relevant down-
stream effector of the RAS signaling, could also promote re-
programming (Figure 1B). In addition, treatment with
MEKi (PD0325901), to blockMAPK activity, during the first
3 days of reprogramming with overexpression of NrasV12
(Figure 1C) caused a dramatic drop in the reprogramming
efficiency, while treatment during the previous 3 days
had only a minimal impact (Figure 1D). These results
show that RAS oncogene overexpression can have a posi-
tive impact on cell reprogramming efficiency, acting at
least in part through MEK, during the early steps of the
process.
To determine if the effect of oncogenic RAS reflected a
neomorphic activity, not shared with endogenous wild-
type (WT) RAS, we assessed the level of activation of endog-
enous RAS activity during cellular reprogramming. For this,
we pulled down GTP-bound active RAS from total cell ex-
tracts obtained during consecutive days along a reprogram-
ming process from WT MEFs overexpressing OSKM (Fig-
ure 1E). Active RAS increased during the first 2 days of
reprogramming, decreasing to normal levels over the re-
maining process (Figure 1F). Similarly, acute increased
expression of phospho-ERK and decreasing levels were
noted as well, and correlated with the RAS pull-down (Fig-
ure 1G). Confirming the early involvement of this endoge-
nous pathway on cellular reprogramming, treatment with
MEKi during the first 3 days of the process (Figure 1H)
caused a dramatic decrease in the number of iPSC colonies
obtained, while the same treatment during the last days
had a minor effect (Figure 1I).
Taken together, our results point to a positive contribu-
tion of endogenous RAS in cell reprogramming, especially
early during the process, an effect that is exacerbated by
the expression of oncogenic mutant RAS.
Gene Expression Changes upon RAS Expression
during Reprogramming
Next, we examined how overexpression of RAS was
affecting pluripotency gene expression during reprogram-
ming. We measured the level of expression of Nanog,
Ssea1, Essrb, andDppa3, all markers of pluripotency, during
cell reprogramming using OSKM expression combined
with HrasV12 or GFP as a control. All these pluripotency
markers consistently reached an increased expression at
later time points when OSKM reprogramming was com-
bined with HrasV12 compared with GFP expression (Fig-
ure 2A), consistent with an increased number of colonies
obtained in this condition. Interestingly, the expression
Figure 1. RAS Expression Enhances Cellular Reprogramming
(A) Representative picture of AP staining after reprogramming of i4F MEFs overexpressing HrasV12, or GFP as a control (left), and
calculation of efficiency of reprogramming relative to GFP (right).
(B) Efficiency of reprogramming obtained after overexpression in MEFs of NrasV12 or BrafV600E, relative GFP as a control.
(C) Schematic representation of experimental setup to test the effect of inhibiting MEK (PD0325901) from T0-T3 compared with T10-T13
during reprogramming with overexpression of NrasV12 on i4F MEFs.
(D) Efficiency of reprogramming obtained after overexpression in i4F MEFs of NrasV12 and treatment with MEKi (PD0325901) during the
first 3 days (T0-T3) or the last 3 days (T10-T13) of reprogramming, compared with vehicle (VEH), and relative to GFP control.
(E) Schematic representation of experimental setup to analyze the levels of active (GTP bound) Ras using a RalGDS-RBD pull-down from
protein extracts obtained along a normal process of cellular reprogramming.
(F) Pull-down assay of active GTP-bound RAS along time points during the process of reprogramming (D0-D10) of WT MEFs transduced with
OSKM. Western blot with antibodies against PAN-Ras showing the levels of active RAS in pull downs (upper panel) and inputs (lower panel).
Representative of three independent experiments.
(G) Western blot showing the levels of active phosphorylated ERK (P-ERK, upper panel) and total ERK (middle panel) along the same
process of reprogramming (D0-D10). Tubulin levels are shown as loading control. Representative of three independent experiments.
(legend continued on next page)
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of Ssea1 was increased from the initial time point and in a
sustainedmanner throughout the whole process of reprog-
rammingwhenHrasV12was expressed (Figure 2A). In addi-
tion, we checked the level of fibroblast cell marker expres-
sion because cell reprogramming implicates a change in
identity from the initial differentiated cell type (in our
case fibroblasts) to the final iPSCs. Both, Thy1 and Fn1
were downregulated when HrasV12 was included in the re-
programming cocktail, with levels already at initial stages
clearly lower than in the control GFP-expressing cells
(Figure 2B).
Oncogenic RAS expression in primary fibroblasts triggers
a form of stable cell-cycle arrest, known as cell senescence
(Serrano et al., 1997) and this is a crucial barrier opposing
reprogramming (Banito and Gil, 2010). We tested if onco-
genic RAS was inducing cell senescence during reprogram-
ming by measuring the expression levels of two critical
genes participating on the cell-cycle arrest that character-
izes cell senescence: Cdkn1a and Ink4a (Collado and
Serrano, 2006). In addition, we also checked the expression
of cytokine Il6, an immune factor that has been linked to
both cell senescence and reprogramming (Mosteiro et al.,
2018). qRT-PCR revealed a transient peak of expression
for Cdkn1a and Ink4a early during reprogramming, and a
more delayed one for Il6, during reprogramming with
HrasV12 (Figure S2A). To more directly assess cell
senescence we measured senescence-associated beta-galac-
tosidase (SAbGal), the most widely used marker of cell
senescence (Dimri et al., 1995), employing a chemilumi-
nescence substrate, Galacton. Cell extracts at various times
of cell reprogramming were collected and assessed for
SAbGal in vitro and the activity plotted relative to the
number of cells. SAbGal activity was generally similar
comparing oncogenic HrasV12-expressing cells and con-
trol cells, except during the first time point, when GFP-ex-
pressing cells showed even higher levels of SAbGal than
HrasV12 cells (Figure S2B). To further confirm these results,
we counted the cell numbers obtained at different time
points during the process. HrasV12 expression caused
a limited increase in the number of cells at around days
5–7, but by the end of the process of reprogramming cell
numbers tended to be similar (Figure S2C).
Thus, the expression of HrasV12 causes changes in plu-
ripotency and cell identity genes that could facilitate cell
reprogramming, with some of these occurring at very early
stages of the process. We wondered whether HrasV12(H) Schematic representation of experimental setup to test the effect
during normal cellular reprogramming on WT MEFs overexpressing OS
(I) Efficiency of reprogramming obtained after treatment with MEKi (
T13) of the process in WT MEFs transduced with OSKM, compared wit
n = 3 independent experiments. All data correspond to the average ± S
test: ***p < 0.001, **p < 0.01, *p < 0.05; n.s., not significant. See a
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for these immediate gene expression changes that we
observed. To address this question, we transduced WT
MEFs with anHrasV12-expressing vector under cell reprog-
ramming conditions of cell culture but omitting OSKM re-
programming factors (Figure 2C), and analyzed the expres-
sion of Ssea1, Thy1, and Fn1 at early time points. qRT-PCR
analysis showed that HrasV12 expression alone was suffi-
cient to cause an increase in the expression of pluripotency
gene Ssea1, while at the same time causing a decrease in
identity genes Thy1 and Fn1 (Figure 2D).
Collectively, our analysis of the dynamics during cell re-
programming in the presence of an active HrasV12 onco-
gene suggests the existence of early gene expression
changes that could promote reprogramming by increasing
pluripotency genes and decreasing cell identity genes.
Ras Increases Cell Reprogramming in a Paracrine
Manner
Next, we wanted to address whether this effect of HrasV12
on reprogramming was cell autonomous. For this, we took
advantage of a tetracycline-inducible HrasV12-expressing
lentiviral vector encoding its own reverse tetracycline-
controlled transactivator (rtTA). We combined HrasV12
expression from this vector with OSKM expression from a
lentiviral vector that was also dependent on tetracycline
but lacked rtTA. In this manner, OSKM expression (and
the ensuing cell reprogramming) could only take place
within cells with concomitant expression of HrasV12 (see
Figure 3A for a diagram depicting the experimental setting
and the vectors used). Using this setting we observed that
cell reprogramming was nearly abolished when OSKM
expression was forced within cells expressing HrasV12
compared with the combination of OSKM with the empty
vector that provides the rtTA (Figures 3B and 3C). Intro-
ducing an extra dose of the empty vector combined with
HrasV12 rescued the deficient reprogramming, since
OSKM expression could now take place independently of
HrasV12 (Figures 3B and 3C). We analyzed the levels of
expression of Il6, a pro-inflammatory cytokine associated
with oncogenic RAS expression and the secretory pheno-
type produced by senescent cells (known as SASP) that
has been reported to favor the reprogramming process in
a paracrine manner (Brady et al., 2013; Mosteiro et al.,
2018). Interestingly, we observed that, in HrasV12 overex-
pressing cells, the levels of Il6 are higher than in the controlof inhibiting MEK (PD0325901) from T0-T3 compared with T10-T13
KM.
PD0325901) during the first 3 days (T0-T3) or the last 3 days (T10-
h vehicle-treated cells (VEH).
D. Statistical significance was assessed by the two-tailed Student’s t
lso Figure S1.
Figure 2. Gene Expression Changes upon
RAS Expression during Reprogramming
(A) qRT-PCR analysis of expression of plu-
ripotency genes Nanog, Ssea1, Essrb, and
Dppa3 after GFP or HrasV12 overexpression in
WT MEFs transduced with OSKM along the
process of cell reprogramming. Levels of
expression for each gene in pluripotent ESCs
(open squares) are shown as a reference.
(B) qRT-PCR analysis of expression of cell
identity genes Thy1 and Fn1 after GFP or
HrasV12 overexpression along the process of
cell reprogramming in WT MEFs transduced
with OSKM.
(C) Schematic diagram showing the experi-
mental setup to study gene expression
changes after HrasV12 expression compared
with control GFP independently of cellular
reprogramming.
(D) qRT-PCR analysis of expression at early
time points of pluripotency gene Ssea1, and
cell identity genes Thy1 and Fn1, in WT MEFs
transduced with HrasV12 independently of
reprogramming.
n = 3 independent experiments. All data
correspond to the average ± SD. of qRT-PCR
data. Statistical significance was assessed by
the two-tailed Student’s t test: ***p < 0.001,
**p < 0.01, *p < 0.05; n.s., not significant.
See also Figure S2.empty vector (Figure 3D). However, this event did not
correlate with reprogramming success, with similarly
high levels of Il6 achieved in the condition that led to effi-
cient reprogramming than in the one with impaired
reprogramming.
These results suggest that the ability of RAS to drive re-
programmingmight be cell non-autonomous, i.e., it might
be changing cells in the neighboring environment, rather
than itself. To directly test this possibility, we decided to
assess the reprogramming efficiency of cells derived from
the i4F mice growing on mixed cultures together with
MEFs transduced with NrasV12 or GFP, as a control (Fig-
ure 3E). Using this system, we observed that the presence
of cells expressing NrasV12 caused a marked increase in
the efficiency of reprogramming compared with control
cells expressing GFP (Figure 3F). In addition, we also per-
formed a reprogramming experiment using i4F MEFs
exposed to conditioned medium (CM) produced by MEFs
transduced with NrasV12 or GFP (Figure 3G). This time,
iPSC colonies were slightly more efficiently, but reproduc-
ibly, formed when i4F MEFs were reprogrammed in the
presence of CM from cells expressing NrasV12 (Figure 3H).
Taken together, these results confirm our interpretation
that the increased efficiency of reprogramming associatedwith RAS overexpression is non-autonomous, pointing to
a mechanism mediated, at least partially, through secreted
factors. Since we had observed that RAS alone can cause
changes in genes related with pluripotency and cell iden-
tity by itself, independently of the reprogramming process,
we evaluated if these changes occur also on target cells
exposed to these factors. For this, we cultured MEFs on a
transwell system, seeding WT target cells on the bottom
chamber and HrasV12- or GFP-transduced MEFs on the
top chamber, and collected the cells after 1, 3, or 5 days
of co-culture (Figure 3I). The analysis of these cells revealed
higher levels of expression of pluripotency gene Ssea1 after
5 days and lower levels of Fn1 on the first day (Figure 3J).
Similarly, WT MEFs cultured for 1, 3, or 5 days in the pres-
ence of CM from MEFs transduced with HrasV12 (Fig-
ure 3K) showed reduced levels of Thy1 expression
compared with cells exposed to CM from GFP-expressing
cells (Figure 3L). These observations are in line with the
idea of these genetic changes taking place as a consequence
of the exposure to factors secreted by RAS-expressing cells.
These results point to a non-autonomous effect caused
by expression of oncogenic RAS on the surrounding cells,
altering the levels of expression of certain genes related to
the acquisition of pluripotency and the loss of cellularStem Cell Reports j Vol. 12 j 1099–1112 j May 14, 2019 1103
Figure 3. RAS Increases Cell Reprogramming in a Paracrine Manner
(A) Schematic diagram of the different lentiviral vectors used in this study: EV is the empty vector carrying the rtTA required for doxy-
cycline-induced expression; OSKM stands for the inducible expression of the reprogramming factors Oct4, Sox2, Klf4, and c-Myc but lacking
rtTA; HrasV12 stands for inducible expression of oncogenic Hras and carrying rtTA. The combination of EV + OSKM allows inducible
expression of OSKM, while the combination of OSKM + HrasV12 forces the co-expression of the reprogramming factors and the active
oncogenic Hras together, by using rtTA encoded in the HrasV12 vector.
(B) Representative picture of AP staining after reprogramming with inducible OSKM in MEFs transduced with inducible HrasV12 alone
(HrasV12) compared with empty vector (EV) (left panel), and the same experiment including an extra dose of empty vector (right
panel, +EV) to rescue reprogramming.
(C) Quantification of the number of AP-positive colonies obtained in (B).
(legend continued on next page)
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identity. This effect seems to bemediated in part by soluble
factors induced by oncogenic RAS.
Oncogenic Activation In Vivo Promotes
Dedifferentiation Events in Non-permissive Tissues
The expression of reprogramming factors in vivo using i4F
mice allows the acquisition of the pluripotent state in cells
of different tissues. However, although the transgenic
cassette is expressed in all mouse tissues examined, not
all are equally susceptible to this dedifferentiation process
(Abad et al., 2013). Interestingly, previous studies showed
how tissue damage and cellular senescence generate an
environment that facilitates reprogramming in resistant
tissues (Chiche et al., 2017; Mosteiro et al., 2016). Consid-
ering this and the results above we wanted to determine if
oncogenic activation in vivo could also favor reprogram-
ming in resistant tissues.
First, we injected mice intramuscularly with 3-methyl-
cholanthrane (3-MCA), a highly carcinogenic polycyclic
aromatic hydrocarbon that generates fibrosarcomas in
mice when injected intramuscularly, with tumors car-
rying frequent oncogenic mutations in RAS oncogenes
(Carbone et al., 1991; Eva and Aaronson, 1983; Watanabe
et al., 1999). We combined 3-MCA injection in the tibia-
lis anterior with the expression of OSKM in vivo in i4F
mice by administration of doxycycline in the drinking
water for 7 days, stopped the treatment and waited for
an additional 3 days before harvesting tissue (Figure 4A).
Using this protocol, we confirmed that the expression of
NANOG and OCT4 by immunohistochemistry in areas
affected in the pancreas, the most susceptible tissue for
dedifferentiation upon OSKM expression (Figure S3A).
Histologic analysis of the tibialis anterior of these
mice revealed extensive damage to muscle fibers upon(D) qRT-PCR analysis of expression of pro-inflammatory cytokine Il6
(E) Schematic diagram showing the experimental setup to study cellu
transduced with NrasV12, or GFP as control.
(F) Reprogramming efficiency (representative picture, left; and quan
MEFs previously transduced with GFP or NrasV12.
(G) Schematic diagram showing the experimental setup to study repro
or GFP as negative control, to i4F MEFs.
(H) Reprogramming efficiency (representative picture, left; and quan
presence of CM from MEFs previously transduced with NrasV12, or GFP
(I) Schematic diagram showing the experimental setup to study the e
released from WT MEFs cultured on the top chamber of transwells and
(J) qRT-PCR analysis of expression of pluripotency gene Ssea1 and cell
of transwells, with MEFs transduced with GFP or HrasV12 independen
(K) Schematic diagram showing the experimental setup to study the ef
transduced with HrasV12 or GFP.
(L) Gene expression analysis on MEFs cultured in the presence of CM
programming.
n = 3 independent experiments. All data correspond to the average ± S
t test: ***p < 0.001, **p < 0.01, *p < 0.05; n.s., not significant.3-MCA, as reflected by the smaller size of the fibers and
the central localization of nuclei within fibers (Figures
4B, 4C, and S3B). This damage was exacerbated by the
combination with doxycycline treatment but was not
observed simply by mock injection or doxycycline alone
(Figure 4B). Immunohistochemical analysis of NANOG
and OCT4 expression in consecutive sections revealed
cells positive for both pluripotency markers only in tis-
sues from 3-MCA-injected i4F animals treated with doxy-
cycline and associated with areas showing muscle fiber
damage and immune cell infiltration, indicating that
the combination of OSKM expression and oncogenic
damage can promote dedifferentiation in the affected tis-
sue (Figure 4C). Using a longer protocol (2.5 weeks) and
lower doxycycline treatment, we obtained similar results,
with positive expression of NANOG and OCT4 in
damaged muscle fibers (Figures S3C and S3D). To extend
our observations to a system of controlled oncogenic
activation and to a different tissue refractory to dediffer-
entiation by OSKM expression, we decided to cross i4F
mice with animals with conditional activation of
KrasV12 from its endogenous allele triggered by the addi-
tion of Cre recombinase (Guerra et al., 2003). Four
months after intratracheal administration of Cre, mice
were treated with doxycycline in the drinking water for
2.5 weeks to induce the expression of OSKM and,
3 days later, mice were sacrificed, lungs were removed,
and immunohistochemical analysis was performed (Fig-
ure 4D). Histological analysis of lung sections after induc-
tion of KrasV12 showed multiple adenomas and a few ad-
enocarcinomas, as expected (Figures 4E and S3E),
Staining with antibodies against OCT4 revealed areas
with positive nuclei associated with pre-malignant,
KrasV12-initiated, lesions, whereas lungs from i4F micein (B).
lar reprogramming in co-cultures of i4F MEFS grown with WT MEFs
tification relative to GFP, right panel) of i4F MEFs co-cultured with
gramming after addition of CM from MEFs transduced with NrasV12,
tification relative to GFP, right panel) of i4F MEFs cultured in the
as negative control.
ffect on the gene expression of WT MEFs exposed to soluble factors
transduced with HrasV12 or GFP.
identity genes Thy1 and Fn1 in MEFs cultured on the bottom chamber
tly of reprogramming on the top chamber.
fect on the gene expression of WT MEFs exposed to CM from WT MEFs
from cells transduced with GFP or HrasV12 independently of re-
D. Statistical significance was assessed by the two-tailed Student’s
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Figure 4. Oncogenic Activation In Vivo Promotes Dedifferentiation Events in Non-permissive Tissues
(A) Schematic representation of 3-MCA injection in the tibialis anterior (TA) of i4F mice followed by treatment with doxycycline for 7 days
at 1 mg/mL. Mice were sacrificed 3 days after stopping doxycycline treatment.
(B) Representative pictures of H&E staining of sections of TA from mice injected with vehicle (left panels) or 3-MCA (right panels), and
untreated (upper panels) or treated with doxycycline (lower panels) (203 magnification).
(C) Representative pictures of immunohistochemical analysis of NANOG (left panels) or OCT4 (right panels) expression on TA from mice
injected with vehicle (upper panels) or 3-MCA (lower panels) and treated with doxycycline (403 magnification, arrows point the
positive cells). Insets show amplified positive cells. Quantifications show the relative percentage of positive cells. Values correspond to
average ± SD (n = 3 mice).
(D) Schematic representation of administration of Ad-Cre to i4F/KrasV12 mice followed by doxycycline treatment for 2.5 weeks at
0.2 mg/mL. Mice were sacrificed 3 days after stopping doxycycline treatment.
(E) Representative picture of a lung section from mouse showing several adenomas (arrow) and adenocarcinoma (*), indicates the correct
induction of expression of KrasV12.
(F) Representative pictures of H&E staining (left panels) or immunohistochemical analysis of OCT4 (right panels) expression on lungs from
mice treated with doxycycline and treated (lower panels) or not (upper panels) with Ad-Cre to induce KrasV12 expression (403 magni-
fication, arrow points to OCT4-positive cells in an adenoma lesion). Quantifications show the relative percentage of OCT4-positive cells.
Values correspond to average ± SD (n = 3 mice). See also Figure S3.
1106 Stem Cell Reports j Vol. 12 j 1099–1112 j May 14, 2019
lacking the KrasV12 transgene were totally negative for
this marker, confirming our observations obtained with
3-MCA in muscle (Figure 4F).
Thus, in vivo evidence from two different mouse models
of oncogene activation combined with OSKM expression
show that oncogene-induced tissue damage cooperates
with reprogramming factor expression to initiate a process
of dedifferentiation that results in the expression of plurip-
otency markers.
Ras Expression in the Context of Full Oncogenic
Transformation Blocks Reprogramming
Since our data show that overexpressing oncogenic RAS en-
hances cellular reprogramming of primary cells, we
wondered whether it would have the same effect on
immortal cells. For this, we transduced HrasV12 on MEFs
deficient for p53 together with reprogramming factors
OSK, omitting c-Myc, since this factor is a potent oncogene
that efficiently cooperates with lack of p53 to transform
cells and it is dispensable for reprogramming (Nakagawa
et al., 2008; Wernig et al., 2008). Expression of HrasV12
in the absence of p53 did not cause increased reprogram-
ming efficiency (Figures 5A and 5B). On the contrary, the
number of iPSC colonies was reduced (Figures 5A and
5B). In parallel, HrasV12 expression enhanced reprogram-
ming by OSKM in WT cells, as expected. Expression levels
ofHrasV12were similar in bothWTand p53-nullMEFs (Fig-
ure 5C). Similar results were observed when MEFs derived
fromanimals deficient in another crucial tumor suppressor,
Arf, were used (Figure S4A). To confirm these results, we ex-
pressed OSKM on three different fibrosarcoma cell lines
derived from tumors developed in mice after injection
with 3-MCA. Despite the presence of increased levels of re-
programming factors Oct4 and Sox2, these fibrosarcoma
cell lines did not produce a single iPSC colony, while con-
trol WT MEFs underwent a typical process of cell reprog-
ramming, as expected (Figures 5D and 5E).
Since we observed that RAS was affecting cellular reprog-
ramming by inducing changes in the expression of plurip-
otency and cell identity genes independently of OSKM
expression inWTcells, we wondered if these same changes
were occurring in p53-null cells (Figure 5F). Gene expres-
sion analysis of mRNA extracted from p53-nullMEFs trans-
duced with HrasV12 or GFP showed reduction in the
expression of cell identity genes, Thy1 and Fn1 (Figure 5G),
similar to what we observed when we used WT MEFs (Fig-
ure 2D). In contrast, the expression levels of pluripotency
gene Ssea1 remained unchanged (Figure 5G), an observa-
tion that is in line with the decreased reprogramming effi-
ciency observed when HrasV12 is expressed in p53-null
cells. Similar gene expression changes were also observed
when p53-null MEFs transduced with HrasV12 or GFP
were seeded on the top chamber of transwells and normalprimary MEFs were seeded on the bottom chamber (Fig-
ure S4B). Cells receiving CM from the transformed MEFs
showed reduced expression of Fn1 and Ssea1, with no
apparent change inThy1 (Figure S4C). Similarly, wewanted
to check the paracrine effect on reprogramming of CM
from p53-nullMEFs expressing NrasV12. For this, we trans-
duced p53-nullMEFs with GFP or NrasV12. CM from these
cell cultures was added to WT MEFs expressing OSKM and
cell reprogramming was assessed (Figure 5H). Cell reprog-
ramming in the presence of CM from p53-null MEFs ex-
pressing NrasV12 was not increased and was even reduced
(Figure 5I).
These results show that, although RAS expression in
normalWTcells increases cell reprogramming, in combina-
tion with another cooperating oncogenic event it hinders
reprogramming.
Reversal of the TransformedPhenotype by TurningOff
RAS Allows Reprogramming
To test the differential effect on cellular reprogramming of
RAS oncogene expression depending on the cellular
context, we decided to set up a reversible system of cellular
transformation (Figure 6A). MEFs deficient for p53 were
transduced with a lentiviral vector for doxycycline-induc-
ible expression ofHrasV12. In these cells, addition of doxy-
cycline leads to the reversible expression of HrasV12 and
the increased formation of colonies of transformed cells
(Figures 6B, S5A, and S5B). When we expressed OSK in
these cells in the presence of doxycycline, i.e., expressing
HrasV12, we observed a drastic reduction in the number
of iPSC colonies compared with the control reprogram-
ming in the absence of the inducer (Figures 6C and 6D).
Interestingly, withdrawal of doxycycline, i.e., shutting
downHrasV12 expression, rescued this block in reprogram-
ming and iPSC colonies were obtained (Figures 6C and 6D).
To explore this phenomenon in vivo, we recapitulated
this experiment to assess the growth of these cells as tu-
mors or teratomas when injected in animals. MEFs defi-
cient in p53 were transduced with the inducible HrasV12
vector andOSK in the presence of doxycycline andwere in-
jected in the kidney of syngenic animals (Figure 6E). In-
jected mice were treated or not with doxycycline in the
drinking water to allow for continuous expression of
HrasV12 or its silencing, and tumor growth was evaluated.
All the animals treated with doxycycline developed tumors
as judged bypathological inspection (6 out of 6) (Figure 6F),
whereas those without treatment developed only tera-
tomas with a lower penetrance (2 out of 7) that showed his-
tological structures characteristic of the three germ layers
and thatwere positive for the expression of specificmarkers
(Figure 6G). Tumors and teratomas were not the result of
the growth of particular cell populations that did not carry
the vectors for the reprogramming factors or for RAS,Stem Cell Reports j Vol. 12 j 1099–1112 j May 14, 2019 1107
Figure 5. RAS Expression in the Context of
Full Oncogenic Transformation Blocks Re-
programming
(A) Representative pictures of AP staining of
WT MEFs transduced with OSKM (upper
panels) and p53-null MEFs transduced
with OSK (lower panels) combined with
expression of GFP (left panels) or HrasV12
(right panels).
(B) Normalized reprogramming efficiency
of (A) relative to control condition, WT
OSKM + GFP.
(C) Western blot of protein extracts from
conditions assessed in (A) analyzing the
expression of p53, HRAS, and actin as
loading control. Representative picture of
n = 3 independent experiments.
(D) Representative pictures of negative AP
staining of fibrosarcoma cell lines transduced
with inducible OSKM and treated with doxy-
cycline. WT MEFs treated in parallel and
showing positive staining are shown as
control.
(E) qRT-PCR expression analysis of re-
programming factors Oct4 (left panel) and
Sox2 (right panel) on fibrosarcoma cell
lines after doxycycline-induced expression
of OSKM (n = 3). WT MEFs expressing
OSKM and ESC are shown as positive
controls.
(F) Schematic diagram showing the experi-
mental setup to study the effect on gene
expression of p53-null MEFs transduced with
HrasV12 or GFP.
(G) qRT-PCR analysis of expression at early
time points of pluripotency gene Ssea1, and
cell identity genes Thy1 and Fn1, in p53-null
MEFs transduced with HrasV12 independently
of reprogramming.
(H) Schematic diagram showing the experi-
mental setup to study the effect of adding CM
from p53-null MEFs transduced with HrasV12
or GFP, on cellular reprogramming of WT MEFs
transduced with OSKM.
(I) AP staining of WT MEFs transduced with OSKM and treated with CM from p53-null MEFs expressing GFP or NrasV12 (left panel) and
quantification of AP-positive colonies (right panel).
n = 3 independent experiments. All data correspond to the average ± SD. Statistical significance was assessed by the two-tailed Student’s
t test: ***p < 0.001, **p < 0.01, *p < 0.05; n.s., not significant. See also Figure S4.respectively, as observed after genotyping by PCR these tis-
sues to detect specifically the presence of these vectors
(Figure S5C).
Therefore, both in vitro and in vivo evidence shows that
the reprogramming barriers raised by oncogenic transfor-
mation can be reverted by turning off the expression of
the driving oncogene.1108 Stem Cell Reports j Vol. 12 j 1099–1112 j May 14, 2019DISCUSSION
Apart from a promising tool for regenerative medicine,
cellular reprogramming is a very useful system to gain
knowledge of processes involving dedifferentiation and
cell identity changes. Cancer development shares
intriguing similarities with reprogramming, sometimes
Figure 6. Effect on Reprogramming of Reversal of the Transformed Phenotype
(A) Schematic diagram showing the experimental setup to study the effect of the transformed phenotype of cellular reprogramming.
Immortal p53-null MEFs were directly transduced with OSKM for reprogramming or previously transduced with doxycycline-inducible
HrasV12 to cause oncogenic transformation. HrasV12-transformed cells were then reprogrammed in the continuous presence of doxycy-
cline (to induce HrasV12 and maintain transformation) or were transduced with OSKM for reprogramming in the absence of doxycycline (to
switch off HrasV12 expression and cause reversal of transformation to an immortal state).
(B) Western blot of protein extracts from cells generated as depicted on (A) analyzing p53, HRAS, and tubulin as loading control. WT and
p53-null MEFs are shown as control. Representative picture of n = 3 independent experiments.
(C) AP staining of p53-null MEFs transduced with inducible HrasV12 and OSK in the absence (–DOX), presence (+DOX) or after withdrawal
(+/–DOX) of doxycycline (upper panel).
(D) Quantification of AP-positive colonies from (C).
(E) Schematic diagram showing the experimental setup to study the effect of the transformed phenotype of cellular reprogramming in vivo.
Similar to that shown in (A), immortal p53-null MEFs were transduced with doxycycline-inducible HrasV12 to cause oncogenic trans-
formation, then these cells were transduced with OSK and injected into the kidney of mice receiving doxycycline (to keep HrasV12
expression) or not (to switch off HrasV12 expression). Mice were histologically analyzed after sacrifice.
(F) Representative picture of H&E staining of a section from a tumor obtained after intrakidney injection of p53-null MEFs transduced with
inducible HrasV12 and OSK in the presence of doxycycline (403 magnification).
(G) Representative pictures of H&E staining (upper panels) and immunohistochemical analysis of sections from teratomas obtained after
intrakidney injection of p53-null MEFs transduced with inducible HrasV12 and OSK in the absence of doxycycline, showing the expression
of CKAE1/AE3 (endoderm), Desmin (mesoderm), and GFAP (ectoderm) (403 magnification).
n = 3 independent experiments. All data correspond to the average ± SD. Statistical significance was assessed by the two-tailed Student’s t
test: ***p < 0.001, **p < 0.01, *p < 0.05; n.s., not significant. See also Figure S5.showing similar patterns of gene expression and with com-
mon barriers opposing the drastic change in cell identity
experienced during both tumorigenesis and reprogram-
ming (Goding et al., 2014).In this article, we addressed the effect of expressing an
activated oncogene, RAS, on cellular reprogramming and
found that the final outcome depends on the cellular
context. In particular, RAS inclusion in the reprogrammingStem Cell Reports j Vol. 12 j 1099–1112 j May 14, 2019 1109
cocktail increases the efficiency of reprogramming of
normal primary cells. We obtained this same result inde-
pendently of the system used to increase RAS expression
and to reprogram the cells. This observation seems not to
be just the result of in vitro manipulation of cells forced to
overexpress RAS but a reflection of the involvement of
endogenous RAS on reprogramming early during the pro-
cess of reprogramming. A similar observation was reported
by others through single-cell transcriptome analysis during
reprogramming that revealed activation of RAS as an early
molecular event (Kim et al., 2015).
Oncogenic RAS caused gene expression changes in plu-
ripotency markers, showing earlier and higher expression
than with control GFP, as well as reductions in mesen-
chymal identity genes, Thy1 and Fn1. The accumulation
of higher numbers of reprogrammed cells at the end of
the process of reprogramming with RAS could account for
the increased levels of expression of some of these pluripo-
tency genes, such as Nanog, Essrb, or Dppa3. Interestingly,
however, some of these changes, such as downregulation
of Thy1 and Fn1 or upregulation of Ssea1, are evident at
very early stages when reprogramming has not yet
occurred. This could imply that RAS alters the pattern of
expression of certain genes independently of OSKM, and
that these changes precede and predispose cells to the pro-
cess of reprogramming. In line with this notion, we
observed that these changes in gene expression are also
induced in cells expressing RAS independently of the re-
programming process and could be part of the oncogene-
induced plasticity that has been reported to contribute to
oncogenesis (Ischenko et al., 2013). This effect seems to
be exerted by RAS on a non-cell-autonomous manner,
since forced expression of reprogramming factors OSKM
with RAS did not result in increased efficiency, with even
a negative impact on the process. Pro-inflammatory cyto-
kine Il6 has been shown previously to be important during
dedifferentiation to pluripotency (Brady et al., 2013) and
was reported recently as a key factor promoting in vivo re-
programming upon OSKM expression, especially when re-
programming factors were combined with damage or
injury to tissues (Chiche et al., 2017; Mosteiro et al.,
2016, 2018). In our case, RAS is capable of inducing Il6
expression independently of the co-expression of OSKM
or not, but this Il6 does not contribute to reprogramming
when OSKM is forced to be expressed in cells with RAS. Re-
inforcing the notion of non-cell-autonomous pro-reprog-
ramming activity induced by RAS expression, we observed
that mixed cultures of cells expressing either RAS or OSKM,
and cellular reprogramming of cells growing in the pres-
ence of CM from RAS-expressing cells, both showed
increased efficiency of reprogramming.
Even though senescence was initially described as a bar-
rier for cell reprogramming in vitro (Banito and Gil, 2010),1110 Stem Cell Reports j Vol. 12 j 1099–1112 j May 14, 2019OSKM expression in vivo leads to the activation of senes-
cence, and secreted factors from these damaged cells
contribute to the dedifferentiation process experienced
by neighboring cells culminating in cellular reprogram-
ming (Chiche et al., 2017; Mosteiro et al., 2016). The
dazzling observation of cellular reprogramming in vivo
implies that tissues present niches that are permissive to
complete dedifferentiation, allowing the reversion of adult
somatic cells back to an embryonic pluripotent state. How-
ever, not all tissues seem to be capable of nurturing
this complete dedifferentiation, despite verifiable expres-
sion of OSKM (Abad et al., 2013). Interestingly, tissue
injury such as bleomycin-induced fibrosis in the lung or
cardiotoxin-induced muscle damage, renders resistant tis-
sues susceptible toOSKM-induced reprogramming (Chiche
et al., 2017; Mosteiro et al., 2016). Given our results
showing increased efficiency of reprogramming after RAS
oncogene expression in vitro, we decided to test the effect
of oncogenic activation in vivo on the putative reprogram-
ming of these same tissues. Interestingly, using two
different mouse models, we observed that expression of
OSKM after oncogene activation inmuscle and lung results
in the appearance of several cells positive for NANOG and
OCT4, pluripotency markers that are not detected in these
tissues when OSKM are expressed alone.
RAS is known to confer on cells a large degree of pheno-
typic plasticity that predisposes them to neoplastic trans-
formation and acquisition of stem cell characteristics
(Chaffer et al., 2011; Ischenko et al., 2013). Our data sup-
port this idea of an increased plasticity induced by RAS un-
derlying either transformation or reprogramming, depend-
ing on the combined action of cooperating genes. In
keeping with this notion, although combined expression
of active RAS and OSKM leads to increased efficiency of re-
programming, expression of RAS in the context of full
neoplastic transformation does not have a positive impact
on reprogramming and can even have a detrimental effect
on the process. Cell identity markers Thy1 and Fn1 show
reduced levels after RAS expression during transformation,
but in this case pluripotency markers are not upregulated.
Interestingly, reversion of the transformed phenotype by
switching off RAS restores the capacity ofOSKM-expressing
cells to dedifferentiate and generate iPSCs. This effect leads
in vivo to the formation of malignant tumors when RAS is
constantly expressed and to teratomas when it is silenced,
clearly showing that neoplastic transformation and reprog-
ramming to pluripotency are incompatible cellular fates.
In summary, cellular reprogramming offers an excellent
opportunity to better understand processes involving
cellular plasticity and cell identity change such as cancer.
Applying induced dedifferentiation by OSKM expression
to cells expressing oncogenic RAS allows the discrimina-
tion of two incompatible cellular fates, pluripotency and
transformation, depending on the cellular context. This
implies that full transformation imposes new barriers to re-
programming that might be fundamental for tumor cell
identity. New findings in this direction could lead us to
novel anticancer therapies, by allowing us to redirect can-
cer cells to a less malignant state through targeting cancer
cell identity.EXPERIMENTAL PROCEDURES
Animals
All animal procedures were approved by University of Santiago de
Compostela Bioethics Committee in compliancewith Principles of
Laboratory Animal Care of national laws. Transgenic i4F animals
and KrasV12-KI were described previously (Abad et al., 2013;
Guerra et al., 2003).
Reprogramming to iPSCs
For reprogramming to iPSCs, we used three different systems: i4F
MEFs were cultured in the presence of doxycycline at a concentra-
tion of 1 mg/mL, and medium was replaced every 48 h during
14 days; WT MEFs were transduced with lentiviral plasmids Tet-
O-FUW-OSKM and FUW-M2rtTA and cultured with doxycycline
as above; or WT MEFs were transduced with retroviral plasmids:
pMXs-Oct4, pMXs-Sox2, pMXs-Klf4, and pMXs-c-Myc (see Sup-
plemental Experimental Procedures for plasmid details), and
cultured in iPSC medium.
After 14 days, cell cultures were fixed with 4% paraformaldehyde
and theAP activitywas detectedwithVector Red Substrate Kit (Vec-
tor Labs) or Alkaline Phosphatase Blue Membrane Substrate Solu-
tion (Sigma-Aldrich) according to the manufacturer’s instructions.
Plates were scanned with Epson Perfection V550 Photo (Epson)
and quantification of positive colonies was performed using
ImageJ software.
Statistical Analyses
The statistical significance of the data obtained was analyzed using
the two-tailed Student’s t test: ***p < 0.001, **p < 0.01, *p < 0.05;
n.s., not significant.
For protein and RNA analysis and extra details see Supplemental
Experimental Procedures in the Supplemental Information.
SUPPLEMENTAL INFORMATION
Supplemental Information can be found online at https://doi.org/
10.1016/j.stemcr.2019.04.006.
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